MMP16 is a marker of poor prognosis in gastric cancer promoting proliferation and invasion.

Li Cao,Qin Xiao,Haihang Zhu,Xuewen Gu,Xiuchun Tian,Jun Liu,Denghao Deng,Chaowu Chen

doi:10.18632/oncotarget.10177

Abstract

Matrix metalloproteinases (MMPs) are closely associated with tumor proliferation, invasion and metastasis. In this study, we determined the MMPs expression and their clinical significances in gastric cancer (GC). We first extensive studied MMPs expression in GC in The Cancer Genome Atlas (TCGA) RNA sequence database and found MMP16 was candidate biomarker in GC. Then we validated clinical significance of MMP16 mRNA expression in 167 GC by RT-PCR. Survival analysis showed that high expression of MMP16 indicated poor overall and disease free survival (P<0.001). The proliferation and invasion potential of GC cells were determined by CCK8, colony formation and Transwell assays. Silencing of MMP16 expression significantly decreased the invasion and proliferation capacity of GC cells (P<0.05). In conclusion, MMP16 was highly expressed and correlated with poor prognosis in GC patients by promoting proliferation and invasion of GC cells. MMP16 could be a novel molecular target and prognostic marker for GC.

Highlights

Gastric cancer (GC) remains one of the most common of cancer related mortality in East Asia, and about percentage of the cases is in China [1, 2]
Using univariate Cox regression model, we identified MMP16 was the only predictor for overall survival (OS) of Matrix metalloproteinases (MMPs) family in The Cancer Genome Atlas (TCGA) database (P=0.001, Table 2 ), Table 1: Clinical characteristics of patients with gastric in TCGA and validation cohort
Aggressive gastric cancer (GC) are characterized by early lymph node metastasis or distant metastasis

Summary

Introduction

Gastric cancer (GC) remains one of the most common of cancer related mortality in East Asia, and about percentage of the cases is in China [1, 2]. The only curative treatment option for GC patients is surgical resection [2]. There have been advances in diagnosis and management, most GC patients present with locally advanced or metastatic disease with a 5-year survival rate of

Objectives

Methods

Results

Conclusion